UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 21.

Strehlow, F; Bauer, S; Martus, P; Weller, M; Roth, P; Schlegel, U; Seidel, S; Scheibenbogen, C; Korfel, A; Kreher, S (2016). Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. Journal of Neuro-Oncology, 129(1):165-171.

Pitter, K L; Tamagno, I; Alikhanyan, K; Hosni-Ahmed, A; Pattwell, S S; Donnola, S; Dai, C; Ozawa, T; Chang, M; Chan, T A; Beal, K; Bishop, A J; Barker, C A; Jones, T S; Hentschel, B; Gorlia, T; Schlegel, U; Stupp, R; Weller, M; Holland, E C; Hambardzumyan, D (2016). Corticosteroids compromise survival in glioblastoma. Brain, 139(Pt 5):1458-1471.

Suchorska, B; Weller, M; Tabatabai, G; Senft, C; Hau, P; Sabel, M C; Herrlinger, U; Ketter, R; Schlegel, U; Marosi, C; Reifenberger, G; Wick, W; Tonn, J C; Wirsching, H G (2016). Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology, 18(4):549-556.

Hoang-Xuan, K; Bessell, E; Bromberg, J; Hottinger, A F; Preusser, M; Rudà, R; Schlegel, U; Siegal, T; Soussain, C; Abacioglu, U; Cassoux, N; Deckert, M; Dirven, C M; Ferreri, A J; Graus, F; Henriksson, R; Herrlinger, U; Taphoorn, M; Soffietti, R; Weller, M (2015). Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncology, 16(7):e322-332.

Weller, Michael; Weber, Ruthild G; Willscher, Edith; Riehmer, Vera; Hentschel, Bettina; Kreuz, Markus; Felsberg, Jörg; Beyer, Ulrike; Löffler-Wirth, Henry; Kaulich, Kerstin; Steinbach, Joachim P; Hartmann, Christian; Gramatzki, D; Schramm, J; Westphal, M; Schackert, G; Simon, M; Martens, T; Boström, J; Hagel, C; Sabel, M; Krex, D; Tonn, J C; Wick, W; Noell, S; Schlegel, U; Radlwimmer, B; Pietsch, T; Loeffler, M; von Deimling, A; Binder, H; Reifenberger, G (2015). Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathologica, 129(5):679-693.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Weller, M; Schlegel, U (2015). Hirntumoren. In: Schwab, S; Schellinger, P; Werner, C; Unterberg, A; Hacke, W. Neuro-Intensiv-Buch. Heidelberg, 609-619.

Eisele, G; Wick, A; Eisele, A C; Clément, P M; Tonn, J; Tabatabai, G; Ochsenbein, A; Schlegel, U; Neyns, B; Krex, D; Simon, M; Nikkhah, G; Picard, M; Stupp, R; Wick, W; Weller, M (2014). Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of Neuro-Oncology, 117(1):141-145.

Reifenberger, G; Weber, R G; Riehmer, V; Kaulich, K; Willscher, E; Wirth, H; Gietzelt, J; Hentschel, B; Westphal, M; Simon, M; Schackert, G; Schramm, J; Matschke, J; Sabel, M C; Gramatzki, D; Felsberg, J; Hartmann, C; Steinbach, J P; Schlegel, U; Wick, W; Radlwimmer, B; Pietsch, T; Tonn, J C; von Deimling, A; Binder, H; Weller, M; Loeffler, M (2014). Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 135(8):1822-1831.

Semmler, A; Garber, Samuel J; Moskau, S; Frisch, C; Eter, N; Schlegel, U; Linnebank, M (2013). An efficient method for fractionated whole rodent brain radiation. Neurological Research, 35(4):355-359.

Heese, O; Vogeler, E; Martens, T; Schnell, O; Tonn, J C; Simon, M; Schramm, J; Krex, D; Schackert, G; Reithmeier, T; Nikkhah, G; Sabel, M; Steiger, H J; Schlegel, U; Löffler, M; Weller, M; Westphal, M (2013). End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. Neuro-Oncology, 15(9):1251-1256.

Linnebank, M; Moskau, S; Kowoll, A; Semmler, A; Bangard, C; Vogt-Schaden, M; Egerer, G; Schackert, G; Reichmann, H; Schmidt-Wolf, I G H; Pels, H; Schlegel, U (2012). Association of transcobalamin c. 776C>G with overall survival in patients with primary central nervous system lymphoma. British Journal of Cancer:1-4.

Patrij, K; Reiser, M; Wätzel, L; Pels, H; Kowoll, A; Herrlinger, U; Engert, A; Linnebank, M; Schackert, G; Vogt-Schaden, M; Egerer, G; Lamprecht, M; Batchelor, T T; Schlegel, U; Schmidt-Wolf, I G H (2011). Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. German Medical Science, 9:Doc11.

Juergens, A; Pels, H; Rogowski, S; Fliessbach, K; Glasmacher, A; Engert, A; Reiser, M; Diehl, V; Vogt-Schaden, M; Egerer, G; Schackert, G; Reichmann, H; Kroschinsky, F; Bode, U; Herrlinger, U; Linnebank, M; Deckert, M; Fimmers, R; Schmidt-Wolf, I G H; Schlegel, U (2010). Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Annals of Neurology, 67(2):182-189.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology, 28(16):2712-2718.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M J; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Reply to M.C. Chamberlain. Journal of Clinical Oncology, 28(33):e696-e697.

Linnebank, M; Moskau, S; Jurgens, A; Simon, M; Semmler, A; Orlopp, K; Glasmacher, A; Bargart, C; Vogt-Schaden, M; Urbach, H; Schmidt-Wolf, I G; Pels, H; Schlegel, U (2009). Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro-Oncology, 11(1):2-8.

Pels, H; Juergens, A; Glasmacher, A; Schulz, H; Engert, A; Linnebank, M; Schackert, G; Reichmann, H; Kroschinsky, F; Vogt-Schaden, M; Egerer, G; Bode, U; Schaller, C; Lamprecht, M; Hau, P; Deckert, M; Fimmers, R; Bangard, C; Schmidt-Wolf, G; Schlegel, U (2009). Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. Journal of Neuro-Oncology, 91(3):299-305.

Weller, M; Schlegel, U; Schackert, G (2009). Hirnmetastasen und Meningeosis neoplastica. In: Domschke, W; Berger, M; Hohenberger, W; Meinertz, T. Therapie-Handbuch. München: Elsevier, Urban & Fischer, P3-1.

Schlegel, U; Weller, M; Westphal, M (2009). Neuroonkologische Therapie. Stuttgart: Kohlhammer.

Weller, M; Schlegel, U (2008). Hirntumoren. In: Schwab, S; Schellinger, P; Werner, C; Unterberg, A; Hacke, W. NeuroIntensiv. Heidelberg: Springer, 577-588.

This list was generated on Thu Jul 27 20:24:57 2017 CEST.